骨髄線維症患者における経口 TP-3654 の研究
中間または高リスクの原発性または続発性骨髄線維症患者における経口 TP-3654 の第 1/2 相、非盲検、用量漸増、安全性、薬物動態、および薬力学研究
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
調査の概要
詳細な説明
Arm 1 will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive treatment with a JAK inhibitor.
Arm 2 will enroll patients who are on a stable dose of ruxolitinib, but who have either lost response or had a suboptimal or plateau in response.
Arm 3 will enroll patients who have been previously treated with a JAK inhibitor (except momelotinib)
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Reyna Bishop
- 電話番号:617-674-6800
- メール:reyna.bishop@us.sumitomo-pharma.com
研究連絡先のバックアップ
- 名前:Jordan Simpson
- メール:jordan.simpson@us.sumitomo-pharma.com
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35294
- 募集
- University of Alabama
-
コンタクト:
- Tiffany Hill
- 電話番号:205-934-9591
-
-
Arizona
-
Tucson、Arizona、アメリカ、85724
- 募集
- The University of Arizona Cancer Center
-
コンタクト:
- Audrey Johnson
- 電話番号:520-694-9084
- メール:audieejayy@arizona.edu
-
-
California
-
Duarte、California、アメリカ、91010
- 募集
- City of Hope
-
コンタクト:
- Michelle Velasquez
- 電話番号:626-218-3524
- メール:mvelaszuez@coh.org
-
Los Angeles、California、アメリカ、90033
- 募集
- University of Southern California
-
コンタクト:
- Shirley Sian
- 電話番号:323-865-0456
- メール:sian_s@med.usc.edu
-
Newport Beach、California、アメリカ、92663
- 募集
- Hoag Family Cancer Institute
-
コンタクト:
- Patrice Jones
- 電話番号:949-764-5501
- メール:patrice.jones@hoag.org
-
-
Colorado
-
Denver、Colorado、アメリカ、80218
- 募集
- Blood Cancer Center
-
コンタクト:
- Brooke Rhodes
- メール:Brookerhodes@sarahcannon.com
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06510
- 募集
- Yale School of Medicine
-
コンタクト:
- Farah Fasihuddin
- 電話番号:203-494-4610
- メール:farah.fasihuddin@yale.edu
-
-
Florida
-
Gainesville、Florida、アメリカ、32608
- 完了
- University of Florida Health Shands Cancer Hospital
-
Miami、Florida、アメリカ、33136
- 募集
- University of Miami
-
コンタクト:
- Alessia Zoso
- 電話番号:305-243-0327
- メール:azoso@miami.edu
-
Miami、Florida、アメリカ、33176
- 募集
- Baptist Health - Miami Cancer Institute
-
コンタクト:
- Firas El Chaer, MD
- 電話番号:786-596-2000
- メール:firas.elchaer@baptisthealth.net
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Emory University
-
コンタクト:
- Suzanne Scott
- 電話番号:404-778-4334
- メール:suzanne.e.scott@emory.edu
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- 募集
- University of Chicago
-
コンタクト:
- Howie Weiner
- メール:HWeiner@bsd.uchicago.edu
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21201
- 募集
- University of Maryland
-
コンタクト:
- Maria Baer, MD
- 電話番号:410-328-8708
- メール:mbaer@umm.edu
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- 募集
- Massachusetts General Hospital
-
コンタクト:
- Gabriela Hobbs, MD
- メール:ghobbs@mgb.org
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- 募集
- University of Michigan
-
コンタクト:
- Kelsey Bolin
- 電話番号:734-936-2193
- メール:kntillma@med.umich.edu
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55455
- 募集
- University of Minnesota
-
コンタクト:
- Naveen Premnath, MD
- メール:premn007@umn.edu
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- 募集
- Washington University of Medicine
-
コンタクト:
- Nicole Gaudin
- 電話番号:314-747-7960
- メール:nrgaudin@wustl.edu
-
-
New Jersey
-
Hackensack、New Jersey、アメリカ、07601
- 募集
- John Theurer Cancer Center at Hackensack University Medical Center
-
コンタクト:
- Parita Patel
- 電話番号:551-996-5900
- メール:parita.patel@hmhn.org
-
-
New York
-
Buffalo、New York、アメリカ、14263
- 完了
- Roswell Park Comprehensive Cancer Center
-
New York、New York、アメリカ、10065
- 募集
- Memorial Sloan Kettering Cancer Center
-
コンタクト:
- Tamanna Haque, MD
- メール:haquet1@mskcc.org
-
New York、New York、アメリカ、10029
- 募集
- Icahn School of Medicine at Mount Sinai
-
コンタクト:
- Gabriela Bello
- メール:gabriela.bello@mssm.edu
-
New York、New York、アメリカ、10065
- 募集
- Weill Cornell Medical Center
-
コンタクト:
- Penina Steward
- 電話番号:212-746-1858
- メール:pes4006@med.cornell.edu
-
The Bronx、New York、アメリカ、10461
- 募集
- Montefiore Cancer Center
-
コンタクト:
- Olivia Orellano
- メール:oorellano@montefiore.org
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27710
- 募集
- Duke Cancer Institute
-
コンタクト:
- Ben Dosan
- メール:benjamin.dosan@duke.edu
-
-
Ohio
-
Columbus、Ohio、アメリカ、43210
- 募集
- Ohio State University
-
コンタクト:
- Molly Brandenburg
- 電話番号:614-366-7951
- メール:Molly.Brandenburg@osumc.edu
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- 募集
- Medical University of South Carolina
-
コンタクト:
- Jared Hortman
- メール:hortman@musc.edu
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- 募集
- Vanderbilt University
-
コンタクト:
- SMPA Investigative Site
-
Nashville、Tennessee、アメリカ、37203
- 募集
- Tri-Star Centennial Medical Center
-
コンタクト:
- Brooke Rhodes
- メール:brooke.rhodes@sarahcannon.com
-
-
Texas
-
Houston、Texas、アメリカ、77054
- 募集
- MD Anderson Cancer Center
-
コンタクト:
- Kurt Schroeder
- 電話番号:713-745-2232
- メール:kdschroe@mdanderson.org
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- 募集
- Huntsman Cancer Institute
-
コンタクト:
- Nicole Fisher
- 電話番号:801-587-7000
- メール:nicole.fisher@hci.utah.edu
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22903
- 募集
- University of Virginia Cancer Center
-
コンタクト:
- Avani Hopkins
- 電話番号:434-243-8108
- メール:AJH7JQE@uvahealth.org
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- 募集
- University of Washington - Fred Hutchinson Cancer Center
-
コンタクト:
- Anna Halpern
- メール:halpern2@uw.edu
-
-
-
-
-
Lincoln、イギリス
- 募集
- Lincoln County Hospital
-
コンタクト:
- SMPA Investigative Site
-
Lincoln、イギリス
- 募集
- United Lincolnshire Hospitals NHS Trust - Pilgrim Hospital
-
コンタクト:
- SMPA Investigative Site
-
London、イギリス
- 募集
- University College London Hospital's NHS foundation Trust
-
コンタクト:
- SMPA Investigative Site
-
Oxford、イギリス
- 募集
- Oxford University Hospitals NHS Foundation
-
コンタクト:
- SMPA Investigative Site
-
-
-
-
-
Alessandria、イタリア、15121
- 募集
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
-
コンタクト:
- SMPA Investigative Site
-
Aviano、イタリア、33081
- 募集
- Istituto Nazionale Tumori, IRCCS Centro di Riferimento Oncologico di Aviano
-
Bologna、イタリア、40138
- 募集
- IRCCS Azienda Ospedaliero -Universitaria Di Bologna - Dipartimento Malattie Oncologiche ed Ematologiche - UO Ematologia
-
コンタクト:
- SMPA Investigative Site
-
Brescia、イタリア
- 募集
- ASST - Spedali Civili di Brescia
-
コンタクト:
- SMPA Investigative Site
-
Meldola、イタリア、47014
- 募集
- IRCCS istituto Romagnolo per lo studio dei tumori "Dino Amadori"
-
コンタクト:
- SMPA Investigative Site
-
Milan、イタリア、20122
- 募集
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
コンタクト:
- SMPA Investigative Site
-
Torino、イタリア、10126
- 募集
- Azienda Ospedaliera Universitaria Citta' Della Salute E della Scienza di Torino
-
コンタクト:
- SMPA Investigative Site
-
-
-
-
-
Adelaide、オーストラリア
- 募集
- Icon Cancer Centre (Ashford Cancer Centre Research)
-
コンタクト:
- Stanley Cheung, MD
- メール:Stanley.Cheung@icon.team
-
-
South Australia
-
Adelaide、South Australia、オーストラリア
- 募集
- Royal Adelaide Hospital
-
コンタクト:
- Christine Hoare
- メール:christine.hoare@sa.gov.au
-
-
Victoria
-
Box Hill、Victoria、オーストラリア
- 募集
- Eastern Health Box Hill Hospital
-
コンタクト:
- SMPA Investigative Site
-
Clayton、Victoria、オーストラリア
- 募集
- Monash University
-
コンタクト:
- SMPA Investigative Site
-
Fitzroy、Victoria、オーストラリア
- 募集
- St Vincent's Hospital Melbourne
-
コンタクト:
- SMPA Investigative Site
-
Melbourne、Victoria、オーストラリア
- 募集
- Peter McCallum Center
-
コンタクト:
- SMPA Investigative Site
-
Richmond、Victoria、オーストラリア
- 募集
- Epworth Healthcare
-
コンタクト:
- SMPA Investigative Site
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T2N 1N4
- 募集
- University of Calgary
-
コンタクト:
- Sonia Cerquozzi
- メール:sonia.cerquozzi@albertahealthservices.ca
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V6T 1Z3
- 募集
- University of British Columbia
-
コンタクト:
- SMPA Investigative Site
-
Vancouver、British Columbia、カナダ、V6T 1Z3
- 募集
- St. Paul's Hospital Hematology/Oncology Research
-
コンタクト:
- Kelsi Sorensen
- 電話番号:604-682-2344
- メール:ksorensen1@providencehealth.bc
-
-
Ontario
-
Hamilton、Ontario、カナダ、L8V 5C2
- 募集
- Juravinski Cancer Center
-
コンタクト:
- SMPA Investigative Site
-
Toronto、Ontario、カナダ、M5G 2M9
- 募集
- Princess Margaret Cancer Center
-
コンタクト:
- Vikas Gupta
- メール:vikas.gupta@uhn.ca
-
-
Quebec
-
Montreal、Quebec、カナダ、H3T 1E2
- 募集
- Jewish General Hospital
-
コンタクト:
- SMPA Investigative Site
-
-
-
-
-
Barcelona、スペイン
- 募集
- Hospital Universitario y Politecnico La Fe
-
コンタクト:
- SMPA Investigative Site
-
Barcelona、スペイン
- 募集
- Institut Catala d'Oncologia
-
コンタクト:
- SMPA Investigative Site
-
Salamanca、スペイン
- 募集
- Hospital Universitario de Salamanca
-
コンタクト:
- SMPA Investigative Site
-
-
-
-
-
Halle、ドイツ
- 募集
- Universitätsmedizin Halle
-
コンタクト:
- SMPA Investigative Site
-
Lübeck、ドイツ
- 募集
- Universitätsklinikum Schleswig-Holstein
-
コンタクト:
- SMPA Investigative Site
-
-
-
-
-
Amiens、フランス、80054
- 募集
- Centre Hospitalier Universitaire D'Amiens
-
コンタクト:
- SMPA Investigative Site
-
Angers、フランス、9000
- 募集
- CHU Angers
-
コンタクト:
- SMPA Investigative Site
-
Lyon、フランス、69495
- 募集
- Centre Hospitalier Lyon Sud
-
コンタクト:
- SMPA Investigative Site
-
Nice、フランス、06200
- 募集
- Hospitalier Universitaire (CHU) de Nice - Hopital de l'Archet
-
コンタクト:
- SMPA Investigative Site
-
Nîmes、フランス、30029
- 募集
- Institut de cancerologie du Gard
-
コンタクト:
- SMPA Investigative Site
-
Nîmes、フランス
- 募集
- Institut de cancerologie du Gard
-
コンタクト:
- SMPA Investigative Site
-
Paris、フランス、75010
- 募集
- Hospital Saint Louis
-
コンタクト:
- SMPA Investigative Site
-
Poitiers、フランス、86021
- 募集
- University Hospital of Poitiers
-
コンタクト:
- SMPA Investigative Site
-
Villejuif、フランス、94805
- 募集
- Institut Gustave Roussy
-
コンタクト:
- SMPA Investigative Site
-
-
-
-
-
Antwerp、ベルギー、2020
- 募集
- ZNA Cadix
-
コンタクト:
- SMPA Investigative Site
-
Antwerp、ベルギー、2030
- 募集
- ZNA Middelheim
-
コンタクト:
- SMPA Investigative Site
-
Ghent、ベルギー、9000
- 募集
- Universitair Ziekenhuis Gent
-
コンタクト:
- SMPA Investigative Site
-
Liège、ベルギー、4000
- 募集
- CHU de Liege
-
コンタクト:
- SMPA Investigative Site
-
-
Vlaams-Brabant
-
Leuven、Vlaams-Brabant、ベルギー、3000
- 募集
- University Hospitals Leuven
-
コンタクト:
- SMPA Investigative Site
-
-
-
-
-
Aichi、日本
- 募集
- Aichi Medical University Hospital
-
コンタクト:
- Akiyoshi Takami
- 電話番号:0561-62-3311
- メール:takami.akiyoshi.490@mail.aichi-med-u.ac.jp
-
Aomori、日本
- 募集
- Aomori Prefectural Central Hospital
-
コンタクト:
- Tomoaki Akagi, MD
- 電話番号:017-726-8111
- メール:tomakagi@med.pref.aomori.jp
-
Chiba、日本
- 募集
- National Cancer Center Hospital East
-
コンタクト:
- Junichiro Yuda, MD
- 電話番号:04-7133-1111
- メール:jyuda@east.ncc.go.jp
-
Fukuoka、日本
- 募集
- Kyushu University Hospital
-
コンタクト:
- Takuji Yamauchi, MD
- 電話番号:092-641-1151
- メール:yamauchi.takuji.355@m.kyushu-u.ac.jp
-
Hokkaido、日本
- 募集
- Hokkaido University Hospital
-
コンタクト:
- Takanori Teshima, MD
- 電話番号:011-716-1161
- メール:teshima@med.hokudai.ac.jp
-
Kamakura、日本、247-8533
- 募集
- Shonan Kamakura General Hospital
-
コンタクト:
- Tomiteru Togano, MD
- 電話番号:0467-46-1717
- メール:t_togano@shonankamakura.or.jp
-
Miyazaki、日本
- 募集
- University of Miyazaki Hospital
-
コンタクト:
- Kazuya Shimoda, MD
- 電話番号:0985-85-1510
- メール:kshimoda@med.miyazaki-u.ac.jp
-
Okayama、日本
- 募集
- Okayama University Hospital
-
コンタクト:
- Noboru Asada, MD
- 電話番号:086-223-7151
- メール:nasada@okayama-u.ac.jp
-
Osaka、日本
- 募集
- The University of Osaka Hospital
-
コンタクト:
- Michiko Ichii, MD
- 電話番号:06-6879-5111
-
Saitama、日本
- 完了
- Saitama Medical Center
-
Sendai、日本
- 募集
- Tohoku University Hospital
-
コンタクト:
- Noriko Fukuhara, MD
- 電話番号:022-717-7000
-
Shizuoka、日本
- 完了
- Shizuoka Cancer Center
-
Tokyo、日本、160-0023
- 募集
- Tokyo Medical University Hospital
-
コンタクト:
- Daigo Akahane, MD
- 電話番号:03-3342-6111
- メール:dakahane@tokyo-med.ac.jp
-
Tokyo、日本
- 募集
- Juntendo University Hospital
-
コンタクト:
- Shuichi Shirane, MD
- 電話番号:03-3813-3111
- メール:sshirane@juntendo.ac.jp
-
Tokyo、日本、179-0072
- 募集
- Nerima Hikarigaoka Hospital
-
コンタクト:
- Akihiko Gotoh, MD
- 電話番号:03-3979-3611
- メール:akgotou@juntendo.ac.jp
-
Tsu、日本
- 募集
- Mie University Hospital
-
コンタクト:
- Yuka Sugimoto, MD
- 電話番号:059-232-1111
- メール:yuka2@clin.medic.mie-u.ac.jp
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Patients must meet all of the following inclusion criteria to be eligible:
Nuvisertib (TP-3654) Monotherapy Arm:
- Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF and intermediate or high-risk primary or secondary MF
- Previously treated with JAK inhibitor(s) and is intolerant, resistant, refractory or has lost response to the JAK inhibitor(s) or is ineligible to be treated with JAK inhibitor
- Fulfill the following clinical laboratory parameters:
- Platelet count ≥ 25 x 10^9 /L, without assistance of growth factors or platelet transfusions
- ANC ≥ 1 x 10^9/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5%
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI or CT scan) within 2 weeks prior to Cycle 1 Day 1.
- Dose escalation: At least 2 symptoms measurable (score ≥ 1) using the MF-SAF
- Dose expansion: At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF
Nuvisertib (TP-3654) + Ruxolitinib Arm:
- Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF and intermediate or high-risk primary or secondary MF
- On ruxolitinib treatment for ≥ 6 months, and on a stable dose of ruxolitinib (5 to 25 mg BID) for ≥ 8 weeks prior to the first dose of nuvisertib, but has either lost response or had a suboptimal or plateau in response
- Fulfills the following clinical laboratory parameters:
- Platelet count ≥ 50 × 10^9/L (without assistance of growth factors or platelet transfusions)
- ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5% at screening
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
- At least 2 symptoms measurable with each score ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
Nuvisertib (TP-3654) + Momelotinib Arm
- Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF and intermediate or high-risk primary or secondary MF
- Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for ≥ 12 weeks, or ≥ 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of ≥ 4 units of red blood cells in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma
- Fulfills the following clinical laboratory parameters:
- Anemic, defined as Hb <10 g/dL or requiring RBC transfusion at baseline
- Platelet count ≥ 50 × 109/L (without assistance of growth factors or platelet transfusions)
- ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
- Peripheral blood blast count < 5% at screening
- Adequate renal function
- Adequate hepatic function
- Adequate coagulation function
- Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
- At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
- ECOG performance status ≤ 1
- Life expectancy ≥ 6 months
Patients meeting any one of these exclusion criteria will be prohibited from participating in this study:
Nuvisertib (TP-3654) Monotherapy Arm:
- Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or not recovered adequately from from surgery prior to first dose.
- Splenic irradiation within 6 months prior to Screening or prior splenectomy.
- Prior allogeneic stem cell transplant within the last 6 months.
- Eligible for allogeneic bone marrow or stem cell transplantation.
- Unresolved Grade ≥ 2 non-hematological toxicity related to prior treatment
- History of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; left ventricular ejection fraction (LVEF) < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1.
- Corrected QT interval > 480msec.
- Prior or concurrent malignancy that could interfere with the investigational regime.
- Known history of chronic liver disease, e.g. portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1.
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Exhibited allergic reactions or sensitivity to nuvisertib, or similar compound.
- Medical condition or GI tract surgery that could impair absorption or result in short bowel syndrome with diarrhea.
- Systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding.
- Pregnant or breastfeeding
- Currently receiving any other investigational agent.
Nuvisertib (TP-3654) + Ruxolitinib Arm:
- Received previous systemic antineoplastic therapy (other than ruxolitinib) or any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Note: Prior treatment with nuvisertib is not allowed. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited)
- Known allergic reactions or sensitivity to nuvisertib, or similar compound.
- Splenic irradiation within 6 months prior to Screening or prior splenectomy
- Prior allogeneic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
- Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible.)
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately prior to first dose.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed).
- Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
- History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF <45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
- Corrected QTcF of > 480 msec
- Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
- History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
- Pregnant or breastfeeding
Nuvisertib (TP-3654) + Momelotinib Arm:
- Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Notes: Prior treatment with momelotinib or nuvisertib is not allowed; in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week. Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper; hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
- Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
- Known allergic reactions or sensitivity to nuvisertib, momelotinib, or any structurally similar drug, or to any component of the formulations of either study intervention
- Splenic irradiation within 6 months prior to screening or prior splenectomy
- Prior allogenic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
- Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible).
- Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately from surgery prior to first dose.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
- Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
- Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed)
- Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
- Presence of Grade ≥ 2 peripheral neuropathy
- History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
- Corrected QTcF of > 480 msec
- Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
- History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
- Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
- Pregnant or breastfeeding
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:アーム 1: ヌビサーチブ (TP-3654)
|
Oral PIM Inhibitor
他の名前:
|
|
実験的:アーム 2: ルキソリチニブにヌビセルチブ (TP-3654) を追加
|
Oral PIM Inhibitor
他の名前:
Oral JAK inhibitor
他の名前:
|
|
実験的:アーム 3: ヌビセルチブ (TP-3654) とモメロチニブの併用
|
Oral PIM Inhibitor
他の名前:
Oral JAK inhibitor
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Determine the incidence of dose-limiting toxicities (DLTs)
時間枠:28 days
|
Number of participants with DLTs |
28 days
|
|
Determine the incidence of treatment emergent adverse events
時間枠:From start of treatment to end of study
|
Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events |
From start of treatment to end of study
|
|
Assess patients for any evidence of preliminary activity by determining the number of patients with ≥ 35% spleen volume reduction (SVR35)
時間枠:From start of treatment to end of study
|
Number of participants with ≥ 35% spleen volume reduction (SVR35) |
From start of treatment to end of study
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of participants achieving objective response by IWG-MRT response criteria
時間枠:From start of treatment to end of study
|
Number of participants achieving complete remission, partial remission, clinical improvement, progressive disease and stable disease. |
From start of treatment to end of study
|
|
Number of participants who have ≥ 25% spleen volume reduction
時間枠:Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.
|
Number of participants who have ≥ 25% spleen volume reduction compared to baseline |
Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.
|
|
Number of participants with ≥ 50% improvement in total symptom score (TSS50) at week 24
時間枠:24 weeks
|
Number of participants who have ≥ 50% total symptom score reduction by MFSAF compared to baseline after 24 weeks of treatment. |
24 weeks
|
|
Determine the change in Patient Global Impression of Change (PGIC) at week 24 through end of study.
時間枠:After 24 weeks of treatment to end of study
|
Change in PGIC score |
After 24 weeks of treatment to end of study
|
|
Determine the incidence of QT interval changes
時間枠:25 hours
|
Changes in QT interval and heart rhythm |
25 hours
|
|
Establish the half-life (t½) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
時間枠:24 hours
|
The estimate of time for the nuvisertib concentration or amount to be reduced by half |
24 hours
|
|
Establish the Area under the plasma concentration versus time curve (AUC) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
時間枠:24 hours
|
The amount of drug exposure over 24 hours period after administration |
24 hours
|
|
Establish the Peak Plasma Concentration (Cmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
時間枠:24 hours
|
The maximum nuvisertib concentration after administration |
24 hours
|
|
Establish the Time of Maximum concentration observed (tmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib
時間枠:24 hours
|
The time to reach maximum nuvisertib concentration |
24 hours
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
骨髄線維症が減少した患者数
時間枠:研究終了まで24週間ごと
|
研究終了まで24週間ごと
|
|
|
ヌビセルチブ併用療法: ベースラインからのヘモグロビンの増加が 1.5 g/dL 以上、または 2 g/dL 以上であることを評価します。
時間枠:治療開始から研究終了まで
|
治療開始から研究終了まで
|
|
|
Nuvisertib 併用療法: 赤血球輸血非依存性ステータスまたは要件の変更を評価する
時間枠:治療開始から研究終了まで
|
治療開始から研究終了まで
|
|
|
Nuvisertib単剤療法:血小板の変化は、ベースライン血小板数<100 x 10^9/lの患者の時間にわたってカウントされます
時間枠:治療の開始から研究の終わりまで
|
治療の開始から研究の終わりまで
|
|
|
Study potential pharmacodynamic (PD) markers of nuvisertib
時間枠:12 months
|
Evaluate exploratory biomarkers, including change in protein phosphorylation and inflammatory cytokines, in peripheral blood samples and bone marrow biopsy samples. |
12 months
|
|
Establish overall survival
時間枠:From start of treatment to end of study
|
The time interval from treatment start date to date of death from any cause |
From start of treatment to end of study
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- BBI-TP-3654-102
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。